Orient Pharma Co., Ltd. (TPEX:4166)
Taiwan
· Delayed Price · Currency is TWD 24.70
+0.40 (1.65%)
At close: Dec 5, 2025
Orient Pharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 127.99 | 107.37 | 22.29 | -28.76 | -102.65 | -171.38 | Upgrade
|
| Depreciation & Amortization | 133.4 | 134.35 | 134.35 | 66.24 | 60.23 | 61.79 | Upgrade
|
| Other Amortization | 1.4 | 1.37 | 1.22 | 2.86 | 4.95 | 4.78 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.22 | - | 0.04 | 0.13 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | 10 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 8.51 | - | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 0.48 | - | - | - | 0.14 | 1.98 | Upgrade
|
| Provision & Write-off of Bad Debts | 11.21 | 16 | 3.44 | - | - | - | Upgrade
|
| Other Operating Activities | 62.87 | 63.38 | 4.94 | 11.15 | -4.12 | 16.76 | Upgrade
|
| Change in Accounts Receivable | -17.5 | -114.4 | -95.37 | -6.31 | 15.12 | -11.03 | Upgrade
|
| Change in Inventory | -68.49 | -56.57 | -43.67 | -62.23 | -25.38 | -36.33 | Upgrade
|
| Change in Accounts Payable | -1.78 | -19.7 | -6.37 | 42.64 | -9.01 | -10.49 | Upgrade
|
| Change in Unearned Revenue | 18.7 | 42.5 | -42.86 | -13.2 | 33.34 | -1.28 | Upgrade
|
| Change in Other Net Operating Assets | 40.84 | 22.71 | -80.99 | -1.14 | -36.17 | -2.75 | Upgrade
|
| Operating Cash Flow | 317.86 | 197.01 | -102.99 | 11.38 | -53.57 | -147.95 | Upgrade
|
| Capital Expenditures | -42.85 | -27.33 | -54.11 | -28.4 | -66.54 | -74.43 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0.26 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.56 | -0.09 | -19.4 | -0.52 | -3.46 | - | Upgrade
|
| Investment in Securities | 15 | 5 | -9 | - | 120 | -120 | Upgrade
|
| Other Investing Activities | -6.76 | -0.06 | -5.5 | -0.42 | 5.81 | -0.17 | Upgrade
|
| Investing Cash Flow | -35.17 | -22.48 | -88.02 | -29.09 | 55.81 | -194.6 | Upgrade
|
| Short-Term Debt Issued | - | - | 246 | - | 129.5 | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | 133 | - | 66 | Upgrade
|
| Total Debt Issued | -733.5 | - | 246 | 133 | 129.5 | 66 | Upgrade
|
| Short-Term Debt Repaid | - | -64.5 | - | -93 | - | -23.5 | Upgrade
|
| Long-Term Debt Repaid | - | -108.86 | -48.1 | -76.79 | -48.79 | -87.65 | Upgrade
|
| Total Debt Repaid | 262.45 | -173.36 | -48.1 | -169.79 | -48.79 | -111.15 | Upgrade
|
| Net Debt Issued (Repaid) | -471.05 | -173.36 | 197.9 | -36.79 | 80.71 | -45.15 | Upgrade
|
| Issuance of Common Stock | 568.57 | - | - | - | - | 400 | Upgrade
|
| Other Financing Activities | - | - | - | - | -1.6 | - | Upgrade
|
| Financing Cash Flow | 97.52 | -173.36 | 197.9 | -36.79 | 79.11 | 354.85 | Upgrade
|
| Foreign Exchange Rate Adjustments | -6.01 | - | - | 0 | -0 | -0.03 | Upgrade
|
| Net Cash Flow | 374.2 | 1.18 | 6.89 | -54.49 | 81.34 | 12.27 | Upgrade
|
| Free Cash Flow | 275.01 | 169.68 | -157.1 | -17.01 | -120.1 | -222.38 | Upgrade
|
| Free Cash Flow Margin | 21.52% | 13.88% | -17.65% | -3.32% | -25.92% | -53.97% | Upgrade
|
| Free Cash Flow Per Share | 1.22 | 0.76 | -0.70 | -0.09 | -0.64 | -1.31 | Upgrade
|
| Cash Interest Paid | 7.4 | 14.42 | 13.42 | 7.44 | 5.62 | 5.41 | Upgrade
|
| Cash Income Tax Paid | 0.79 | 2.93 | 0.04 | 1.37 | 3.9 | 0.02 | Upgrade
|
| Levered Free Cash Flow | - | 96.9 | -188.04 | -11.17 | -101.34 | -160.99 | Upgrade
|
| Unlevered Free Cash Flow | - | 105.63 | -179.35 | -6.56 | -97.77 | -157.63 | Upgrade
|
| Change in Working Capital | -28.23 | -125.45 | -269.26 | -40.24 | -22.11 | -61.88 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.